In particular, ABT-737, a non-selective Bcl-2/Bcl-XL inhibitor can actually affect the ER–mitochondrial contact site, thereby enhancing the response to cisplatin in ovarian cancer cells [49,50,51]. Here, BCL2L1 is linked to ovarian cancer.